Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous iPSC-Derived RPE Transplantation for Geographic Atrophy in AMD
NCT04339764Phase 2Recruiting
- Sponsor
- National Eye Institute
- Start
- Sep 2020
- Primary completion
- May 2029
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in geographic atrophy (GA) and age-related macular degeneration (AMD), sponsored by National Eye Institute. Primary endpoints: Summary of Adverse Events at 60 months and Visual Acuity Change at 60 months. Started Sep 2020; status: recruiting.
02
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT04339764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339764.